- Technology and Data
- Front End Sales and Marketing
- Allergy
- HIV
- Women's Health
- Migraine
- Compounding
- Continuous Glucose Monitoring
- Mental Health Awareness
- Veterinary Pharmacy
- CBD
- Infectious Disease
- Eye Health
- Digestive Health
- Biosimilars
- Influenza
- Shingles
- COPD Management
- Pediatrics
- Generics
- Pain Management
- COVID-19
- Immunization
- Oncology
- Anticoagulants
- Autoimmune Diseases
- Dermatology
- Diabetes
- Respiratory
- Heart Health
- Cardiovascular Clinical Consult
Smart Injector Insulin Pen Device, Mallya, Cleared by FDA
Mallya can provide convenience for insulin pen users; however, it has yet to be released in the United States.
In December 2022, Mallya, a smart sensor that attaches to insulin pen injectors and turns a disposable pen into a device that connects to smartphones, was cleared by the FDA.
This device helped insulin pen users track their treatment information like dose taken, date, and time of injection. The information is then stored in the Mallya app via Bluetooth. The app is available for both Apple and Android smartphones.
Mallya has the ability to track dosing of glucagon-like peptide 1 (GLP-1) receptor agonists. According to the manufacturer Biocorp, this is the first device in the United States that is able toautomatically connect insulin and GLP-1 injector pens to an app. Mallya is compatible with most popular insulin pens.
Biocorp is currently partnering with Novo Nordisk, Sanofi, and Roche Diabetes Care to improve the current design of Mallya. This device can attach to many different disposable injection pens and track dosing for basal and bolus insulin and GLP-1 receptor agonists. It can easily transfer to new pens thanks to its easy installation and removal.
The device has a 2-year lifespan and requires charging once a month with the average use of 3 to 4 injections per day. Mallya can be charged using via USB. Additionally, the app can connect multiple Mallya devices for those who require multiple types of insulin.
Despite its FDA clearance, Mallya is not yet available and Biocorp has yet to announce and official launch date for the United States.
Reference
1. Briskin, A. FDA Clears Smart Injector Pen Device. diaTribe Learn. January 17, 2023. Accessed January 23, 2023.
Examining Barriers to Care in Diabetic Retinopathy Screening
November 30th 2023Prior research has shown the association between various socioeconomic variables and lower adherence to diabetic retinopathy screening, but few have elaborated on the patient perspective to understand the reason behind this association.
Assessing a National Health Program to Prevent the Onset of Type 2 Diabetes in High-Risk Patients
November 16th 2023An analysis on the Diabetes Prevention Program in England found it was effective at improving key cardiovascular risk factors, including glycated hemoglobin and excess body weight.
AMCP Poster Suggests GLP-1, DPP4 Duplicative Prescribing Cutbacks to Reduce Drug Spending
November 4th 2023A poster presented at AMCP Nexus 2023 outlined how a Pharmacy Therapeutics program yielded $7,500 in savings per patient and $3.5 million in savings overall by reducing patients' incretin therapy prescriptions from two to one.
